Prediction of the lenalidomide toxicity and its therapeutic efficacy in multiple myeloma patients by measuring its plasma concentratio
Not Applicable
- Conditions
- multiple myeloma
- Registration Number
- JPRN-UMIN000022257
- Lead Sponsor
- Japan Community Health care Organization Kyoto Kuramaguchi Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Multiple myeloma patient who recieved anti-cancer drugs in additon to lenalidomide
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hematological and non-hematological adverse event
- Secondary Outcome Measures
Name Time Method Continuity of initial dosage, Hematological response